platinum resistant ovarian cancer | Biotech Strategy Blog

PharmaMar’s lurbinectedin misses in platinum-resistant ovarian cancer

Some brief notes on lurbinectedin in ovarian cancer and small-cell lung cancer (SCLC)… and a warning!

To learn more and get a heads up on our thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Biotech Strategy questions answered on BRAF, MEK, immunotherapy, mirvetuximab soravtansine and venetoclax

Last month’s Biotech Strategy mailbag – where we answer questions from subscribers – turned out to be rather controversial with strong feelings running in several camps on Puma Biotech’s neratinib in breast cancer.

This time around we have a bunch of questions on completely different topics and compounds to cover:

BRAF plus MEK and/or immunotherapy in BRAFV600 metastatic melanoma
Immunogen’s IMGN853 – now known as mirvetuximab soravtansine – in platinum resistant ovarian cancer
AbbVie/Genentech’s ABT–199/GDC–0199 venetoclax

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.

This content is restricted to subscribers

Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘platinum resistant ovarian cancer’

PharmaMar’s lurbinectedin misses in platinum-resistant ovarian cancer

To learn more and get a heads up on our thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

Biotech Strategy questions answered on BRAF, MEK, immunotherapy, mirvetuximab soravtansine and venetoclax

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.